Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
snx-5422 (12 trials)
ibrutinib (imbruvica) (2 trials)
Adenocarcinoma (Phase 1)
Adenocarcinoma of Lung (Phase 1)
Hematologic Neoplasms (Phase 1)
Lymphoma (Phase 1)
Neoplasms (Phase 1)
Neuroendocrine Tumors (Phase 1)
Trials (12 total)
Trial APIs (2 total)